Hewitson, T
Other non-specific symptoms can be present, i.e
Klein EA, Thompson IM Jr, Tangen CM, et al
Adenosylcobalamin (energy production) works well with patients with low energy, often given in combination with hydroxocobalamin
Discontinuation due to adverse events ran 4.1 percent at 4 mg, 6.9 percent at 9 mg, and 11.3 percent at 12 mg, compared with 4.9 percent on placebo
GLP-1 receptor agonists approved for use in the UK include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), exenatide (Byetta, Bydureon), and lixisenatide (Lyxumia)